share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/12/06 14:10

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.
Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.
Adial Pharmaceuticals已通過新的三年期修訂和重述的僱傭協議續簽了首席執行官Cary Claiborne的合同,該協議自2024年12月5日起生效。該協議取代了他2021年12月的先前合同和2022年8月的後續修訂。根據新條款,Claiborne的獎金目標已提高到其基礎薪資的50%,這取決於董事會確定的目標的實現。此外,他在公司2017年股權激勵計劃下獲得了350,000股的股票期權授予,股份將按照比例每月解鎖,持續36個月。
Adial Pharmaceuticals已通過新的三年期修訂和重述的僱傭協議續簽了首席執行官Cary Claiborne的合同,該協議自2024年12月5日起生效。該協議取代了他2021年12月的先前合同和2022年8月的後續修訂。根據新條款,Claiborne的獎金目標已提高到其基礎薪資的50%,這取決於董事會確定的目標的實現。此外,他在公司2017年股權激勵計劃下獲得了350,000股的股票期權授予,股份將按照比例每月解鎖,持續36個月。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息